Published in Ann Surg on October 01, 2006
Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis C. Can J Gastroenterol (2013) 0.83
New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83
Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. World J Gastroenterol (2014) 0.81
Optimal utilization of extended hepatic grafts. Surg Today (2009) 0.80
Mechanisms and consequences of injury and repair in older organ transplants. Transplantation (2014) 0.80
The outcomes of patients with severe hyperbilirubinemia following living donor liver transplantation. Dig Dis Sci (2013) 0.78
Challenges of recurrent hepatitis C in the liver transplant patient. World J Gastroenterol (2014) 0.77
Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients. HPB (Oxford) (2013) 0.75
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Projecting future complications of chronic hepatitis C in the United States. Liver Transpl (2003) 3.84
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Hepatocellular carcinoma and hepatitis C in the United States. Hepatology (2002) 3.00
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology (2002) 2.15
Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology (1998) 1.95
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology (2005) 1.82
Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl (2004) 1.76
Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl (2004) 1.74
A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg (2001) 1.73
Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg (2005) 1.73
Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology (2004) 1.65
Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut (2002) 1.65
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology (1999) 1.59
Hepatitis C and liver transplantation. J Hepatol (2001) 1.40
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology (2003) 1.19
Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl (2004) 1.12
One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl (2004) 1.07
A model to predict severe HCV-related disease following liver transplantation. Hepatology (2003) 1.06
Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transplant (2003) 1.05
The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology (1998) 1.03
Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl (2000) 1.00
Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl (2003) 1.00
Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation (1998) 0.97
Features of the CD4+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels. J Hepatol (2002) 0.95
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl (2002) 0.92
Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol (2004) 0.91
Retransplantation for recurrent hepatitis C. Liver Transpl Surg (1997) 0.90
Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc (2001) 0.89
Hepatitis C virus recurrence after liver transplantation: relationship to anti-HCV core IgM, genotype, and level of viremia. Am J Gastroenterol (1997) 0.89
Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl (2006) 0.88
Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation (1996) 0.86
Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. Liver Transpl Surg (1997) 0.85
The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation (1995) 0.84
Distribution of infecting hepatitis C virus genotypes in end-stage liver disease patients at a large American transplantation center. J Infect Dis (1997) 0.83
Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl (2005) 0.82
Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation (1998) 0.79
Factors that influence the severity of recurrent hepatitis C virus following liver transplantation. Clin Liver Dis (2003) 0.79
Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial. Transplant Proc (2001) 0.78
Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Tissue Antigens (1998) 0.78
Hepatitis C recurrence after liver transplantation. Liver Transpl (2000) 0.77
A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med (2013) 9.97
Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med (2006) 4.31
Choledochoduodenostomy is a safe alternative to Roux-en-Y choledochojejunostomy for biliary reconstruction in liver transplantation. World J Surg (2009) 3.47
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol (2004) 3.27
Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver Transpl (2002) 2.98
Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology (2005) 2.90
Hepatic ischemia/reperfusion injury--a fresh look. Exp Mol Pathol (2003) 2.81
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol (2010) 2.63
Randomized controlled trial of trigeminal nerve stimulation for drug-resistant epilepsy. Neurology (2013) 2.62
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology (2008) 2.48
Selective use of computed tomography compared with routine whole body imaging in patients with blunt trauma. Ann Emerg Med (2011) 2.45
ASC/caspase-1/IL-1β signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology (2013) 2.45
Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology (2002) 2.38
Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transpl (2010) 2.30
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Use of electrochemical DNA biosensors for rapid molecular identification of uropathogens in clinical urine specimens. J Clin Microbiol (2006) 2.27
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 2.26
Incisional hernia after liver transplantation. J Am Coll Surg (2006) 2.23
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Surgical privileging and credentialing: a report of a discussion and study group of the American Surgical Association. J Am Coll Surg (2009) 2.18
Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. J Am Coll Surg (2009) 2.16
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm (2008) 2.16
Ammonia levels and the severity of hepatic encephalopathy. Am J Med (2003) 2.14
Liver transplantation in highest acuity recipients: identifying factors to avoid futility. Ann Surg (2014) 2.13
Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. Transplantation (2015) 2.13
Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg (2007) 2.12
Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology (2005) 2.04
Posttraumatic pneumatocele. J Am Coll Surg (2005) 2.02
Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol (2004) 2.01
Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol (2009) 1.97
Characteristics of highly ranked applicants to general surgery residency programs. JAMA Surg (2013) 1.81
Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology (2004) 1.80
Is the use of pan-computed tomography for blunt trauma justified? A prospective evaluation. J Trauma (2009) 1.79
MELD fails to measure quality of life in liver transplant candidates. Liver Transpl (2005) 1.79
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg (2005) 1.73
Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl (2003) 1.71
Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg (2007) 1.69
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology (2005) 1.66
Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). Gastrointest Endosc (2010) 1.65
Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg (2008) 1.65
Assessment of hepatic steatosis by transplant surgeon and expert pathologist: a prospective, double-blind evaluation of 201 donor livers. Liver Transpl (2013) 1.62
Chronic viral hepatitis and hepatocellular carcinoma. World J Surg (2007) 1.62
Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. Hepatology (2002) 1.62
The protective function of neutrophil elastase inhibitor in liver ischemia/reperfusion injury. Transplantation (2010) 1.62
A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One (2010) 1.62
Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med (2008) 1.61
Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathway. Hepatology (2013) 1.60
Type I, but not type II, interferon is critical in liver injury induced after ischemia and reperfusion. Hepatology (2008) 1.59
Operative parameters that predict the outcomes of hepatic transplantation. J Am Coll Surg (2003) 1.58
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58